PT - JOURNAL ARTICLE AU - Emil Lesho AU - Brendan Corey AU - Francois Lebreton AU - Ana C. Ong AU - Brett E. Swierczewski AU - Jason W. Bennett AU - Edward E. Walsh AU - Patrick Mc Gann TI - Emergence of the E484K Mutation in SARS-CoV-2 Lineage B.1.1.220 in Upstate New York AID - 10.1101/2021.03.11.21253231 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.11.21253231 4099 - http://medrxiv.org/content/early/2021/03/23/2021.03.11.21253231.short 4100 - http://medrxiv.org/content/early/2021/03/23/2021.03.11.21253231.full AB - Ongoing surveillance detected a SARS-CoV-2 B.1.1.220 variant carrying the E484K substitution in four patients from a hospital network in upstate New York. Patients reported no travel history and shared no obvious epidemiological linkage. A search of online databases identified 12 additional B.1.1.220 with E484K, all of which were detected in New York since December 2020. Detailed genomic analyses suggests that the mutation has emerged independently in at least two different B.1.1.220 strains in this region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by the Defense Health Program (DHP) Operations & Maintenance (O&M).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB Approval has been granted for this study by Rochester Regional Health under protocol "IRB 2051 C Lesho: Enhanced Surveillance to Prevent Nosocomial Transmission of SARS-CoV-2 at Rochester Regional Health"All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sequences of the five strains described in this paper have been uploaded to GISAID with Accession ID (virus name): EPI_ISL_1184113(hCoV-19/USA/NY-RRHS-101/2021), EPI_ISL_1184114 (hCoV-19/USA/NY-RRHS-102/2021), EPI_ISL_1184135 (hCoV-19/USA/NY-RRHS-114/2021), EPI_ISL_1184136 (hCoV-19/USA/NY-RRHS-115/2021), and EPI_ISL_1184137 (hCoV-19/USA/NY-RRHS-120/2021).